Clinical trial NCT04349657: A Study Evaluating the Endovascular Treatment of Subjects with Stenotic or Restenotic Lesions of the Common Femoral Artery with the Supera Vascular Mimetic Implant Compared to Surgical Common Femoral Artery Endarterectomy
Official title: An RCT Evaluating the Safety and Efficacy of the Endovascular Treatment of Subjects with Stenotic or Restenotic Lesions of the Common Femoral Artery with the Supera Vascular Mimetic Implant Compared to Surgical Common Femoral Artery Endarterectomy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Peripheral Arterial Disease
Lead sponsor: ID3 Medical
Sponsor class: OTHER
First posted: 2020-04-16
Enrollment: 286
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The subjects will be randomly assigned in a 1:1 manner to treatment with either the Supera stent or endarterectomy.
Primary purpose: TREATMENT

Brief summary: The SUPERSURG RCT trial investigates the efficacy and safety of the endovascular treatment of stenosis or restenosis in the common femoral artery (CFA) of patients presenting with Rutherford classification 2,3 or 4 with a Supera Vascular Mimetic Implant of Abbott, compared to classic surgical common femoral artery endarterectomy. The Supera Vascular Mimetic Implant has an interwoven design and has a high crush resistance and is, when correctly implanted, an ideal stent to treat eccentric calcified plaques in the CFA.

An expected total of 143 patients will be treated with the Vascular Mimetic Implant of Abbott and compared to a control group of another 143 patients that will be treated with classic surgical endarterectomy of the common femoral artery. Assignment to the treatment groups will be at random.

Patients will be invited for a follow-up visit at 1, 6, 12, 24 and 36 months post-procedure.

The primary efficacy endpoint is defined as follows: freedom from clinically-driven target lesion revascularization and binary restenosis at 12 months. The primary safety endpoint is defined as follows: a composite of overall death, cardiac, pulmonary, renal complications, sepsis, target lesion revascularisation and wound related complications through 30 days post-index procedure.

The secondary endpoints are defined as technical success, primary patency in the deep femoral artery, primary patency in the target lesion, target lesion revascularisation, target vessel revascularisation, binary restenosis, duration of initial hospital stay, sustained clinical improvement, change of walking impairment questionnaire score from baseline, change in target limb Rutherford classification, change in target limb ABI/TBI from baseline, all cause death, thrombosis at the target lesion through 6, 12, 24 and 36 months post-procedure.

Detailed description: The objective of this clinical investigation is to assess the safety and efficacy of the Supera Vascular Mimetic Implant for the treatment of stenotic or restenotic lesions of the common femoral artery. Furthermore, a non-inferiority hypothesis in terms of efficacy and a superiority in terms of safety will be tested with the endovascular treatment with Supera compared to surgical endarterectomy of the common femoral artery.

The patients will be selected based on the investigator's assessment, evaluation of the underlying disease and the eligibility criteria. The patient's medical condition should be stable, with no underlying medical condition which would prevent them from performing the required testing or from completing the study. Patients should be geographically stable, willing and able to cooperate in this clinical study, and remain available for long term follow-up. The patient is considered enrolled in the study after obtaining the patients informed consent, if there is full compliance with the study eligibility criteria and after successful guidewire passage through the study target lesion.

Prior to the index procedure the following will be collected: an informed consent for data collection, demographics, medical history, medication record, physical examination, clinical category of acute limb ischemia (Rutherford category), the resting ankle-brachial index (ABI) or toe-brachial index (TBI), blood sample test (complete blood count, comprehensive metabolic panel and if applicable pregnancy test) and a walking impairment questionnaire. Randomization will also occur prior to the procedure.

During the procedure patients that are randomized within the endarterectomy group will be treated according to the institutions standard of care. For patients that are randomized within the Supera arm, the guidewire will cross the entire study lesion after which the lesion will be assessed through angiography. Pre-dilatation of the target lesion with an uncoated PTA-balloon is mandatory and will be followed by stenting with the Supera stent according to the instructions for use. Postdilatation of the stent is allowed but not mandatory.

The regular follow-up is necessary to monitor the condition of the patient and the results of the procedure. The patients will be invited for the following required follow-up visits at 1, 6, 12, 24 and 36 months. During these visit the following data will be collected: medication record, physical exam, target limb ABI/TBI and Rutherford classification, duplex ultrasound of target vessel, walking impairment questionnaire and possible adverse events.

Eligibility criteria: Inclusion Criteria:

* Patient is ≥18 years old
* Patient presenting a score from 2 to 4 following Rutherford classification
* Patient is willing to comply with specified follow-up evaluations at the specified times
* Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
* Patient has a life expectancy of at least 12 months
* Prior to enrolment, the guidewire has crossed the target lesion in the endovascular arm. In the surgical arm, the endarterectomy needs to be performed with primary suture or patch implantation
* De novo stenotic or restenotic (post-PTA) lesions (\<100%) located in the common femoral artery, suitable for both endovascular therapy and endarterectomy
* Target lesion is located within the native CFA: localized between 1cm proximal to the origin of the circumflex iliac artery and the proximal (2cm) superficial femoral artery and deep femoral artery (2cm) (Azéma type 2 and 3 lesions)
* There is angiographic evidence of a patent deep femoral artery and/or superficial femoral artery
* The target lesion has angiographic evidence of \>50% stenosis. Occlusions are not allowed.

Exclusion Criteria:

* Presence of another stent in the target vessel that was placed during a previous procedure
* Previous open surgery in the ipsilateral groin
* Patients contraindicated for antiplatelet therapy, anticoagulants or thrombolytics
* Patients who exhibit persistent acute intraluminal thrombus at the target lesion site
* Patients with known hypersensitivity to nickel-titanium and heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II
* Known allergy to contrast media that cannot be adequately pre-medicated prior to study procedure
* Patients with uncorrected bleeding disorders
* Female patients with child bearing potential not taking adequate contraceptives or currently breastfeeding
* Ipsilateral inflow (aorto-iliac) artery treatment before target lesion treatment with a residual stenosis \>30%
* Use of thrombectomy, atherectomy or laser device during procedure
* Any patient considered to be hemodynamically unstable at onset of procedure
* Severe medical comorbidities (untreated coronary artery disease/congestive heart failure, severe chronic obstructive pulmonary disease, metastatic malignancy, dementia, etc.) or other medical condition that would prelude compliance with the study protocol or 1-year life expectancy
* Major distal amputation (above the ankle) in the study limb or non-study limb
* Target lesion involves an (pseudo-)aneurysm or is adjacent to an (pseudo-)aneurysm (within 5mm)
* Iliac inflow disease requiring treatment, unless the iliac artery disease is successfully treated first during the index procedure. Success is defined as ≤30% residual diameter stenosis without death or major complications
* Presence of an aortic, iliac or femoral artificial graft
* Occlusion in the target lesion
* Presence of an interposition graft with/without profunda reimplantation

Primary outcomes:
measure: Primary efficacy endpoint at 12 months: Primary patency
timeFrame: 12 months post-index-procedure
measure: Primary safety endpoint at 30 days post-index procedure
timeFrame: 30 days post-index-procedure
Secondary outcomes:
measure: Technical success: post-procedure residual stenosis <30%
timeFrame: Index procedure
measure: Primary patency in the deep femoral artery (DFA), post-index procedure and at 6-, 12-, 24- and 36-months post-index procedure
timeFrame: 6, 12, 24 and 36 months post-index-procedure
measure: Primary patency at 6, 24 and 36 months
timeFrame: 6, 24 and 36 months post-index-procedure
measure: TLR at 6-, 12-, 24- and 36-months post-index procedure
timeFrame: 6, 12, 24 and 36 months post-index-procedure
measure: TVR at 6-, 12-, 24- and 36-months post-index procedure
timeFrame: 6, 12, 24 and 36 months post-index-procedure
measure: Binary restenosis at 6, 12, 24 and 36 months
timeFrame: 6, 12, 24 and 36 months post-index-procedure
measure: Duration of initial hospitalisation stay
timeFrame: Up to 4 weeks
measure: Sustained clinical improvement at 6-, 12-, 24- and 36-months post-index procedure
timeFrame: 6, 12, 24 and 36 months post-index-procedure
measure: Change in Walking Impairment Questionnaire (WIQ) score from baseline to 6, 12, 24 and 36 months
timeFrame: 6, 12, 24 and 36 months post-index-procedure
measure: Change in target limb Rutherford class from baseline to 6, 12, 24 and 36 months
timeFrame: 6, 12, 24 and 36 months post-index-procedure
measure: Change in target limb resting ABI or TBI from baseline to 6, 12, 24 and 36 months
timeFrame: 6, 12, 24 and 36 months post-index-procedure
measure: All cause death at 6, 12, 24 and 36 months
timeFrame: 6, 12, 24 and 36 months post-index-procedure
measure: Thrombosis at the target lesion at 6, 12, 24 and 36 months
timeFrame: 6, 12, 24 and 36 months post-index-procedure
Other outcomes:
Locations:
city: Aalst
country: Belgium
facility: O.L.V. Hospital
city: Bonheiden
country: Belgium
facility: Imelda Hospital
city: Dendermonde
country: Belgium
facility: A.Z. Sint-Blasius
city: Genk
country: Belgium
facility: Z.O.L.
city: Kortrijk
country: Belgium
facility: Az Groeninge
city: Mechelen
country: Belgium
facility: AZ Sint-Maarten
city: Vilvoorde
country: Belgium
facility: A.Z. Jan Portaels
city: Maastricht
country: Netherlands
facility: Maastricht UMC+
state: Limburg
city: Hoorn
country: Netherlands
facility: Dijklander hospital
state: Noord-Holland
city: Alkmaar
country: Netherlands
facility: Noordwest ziekenhuisgroep
city: Utrecht
country: Netherlands
facility: St Antonius Hospital
city: Kraków
country: Poland
facility: Bonifraterskie Centrum Medyczne
city: Poznań
country: Poland
facility: Karol Marcinkowski Medical University
Study officials:
affiliation: A.Z. Sint-Blasius
name: Koen Deloose, MD
role: PRINCIPAL_INVESTIGATOR
References: